Reluctance in SGLT-2 inhibitors usage

Understanding the reluctance in using SGLT2 inhibitors as drug of choice despite of its cardioprotective and renoprotective properties

Published On 2021-10-06 10:46 GMT | Update On 2021-10-20 09:42 GMT

...

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Dr Umesh Khanna

Dr. Umesh B Khanna is a Consultant Nephrologist & Transplant Physician based in Mumbai, practicing at Lancelot Kidney & GI Centre in Borivali West. He holds a MD and DNB from Seth G S Medical College and KEM Hospital in Mumbai. Dr. Khanna has been in private practice for over 25 years, since May 1987. He is also serving as a Director at Kidney Associates.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Reluctance in SGLT-2 inhibitors usage

Understanding the reluctance in using SGLT2 inhibitors as drug of choice despite of its cardioprotective and renoprotective properties

Similar News